Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

被引：19
作者：
Han, Chanhee [1 ]
Bellone, Stefania [1 ]
Zammataro, Luca [1 ]
Schwartz, Peter E. [1 ]
Santin, Alessandro D. [1 ]
机构：
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2018年 / 25卷
关键词：
Binimetinib; MEK162; Low-grade ovarian cancer; Serous; Recurrent; Treatment-resistant;
D O I：
10.1016/j.gore.2018.05.011
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Background: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC. CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation experienced a dramatic clinical response to Binimetinib (MEK162), a mitogen-activated protein kinase (MEK) inhibitor, after failing multiple chemotherapy and hormonal treatments. An 81% reduction of target lesions by RECIST 1.1 over 31 months of response duration was confirmed with serial CT scans. Episodes of drug-related toxicity (pneumonitis) easily resolved without sequelae with the use of oral steroids. Conclusion: Binimetinib may present a new treatment option for hormone-and chemotherapy-resistant LGSOC harboring KRAS mutations.
引用
收藏
页码：41 / 44
页数：4
相关论文
共 12 条
  • [1] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    Ascierto, Paolo A.
    Schadendorf, Dirk
    Berking, Carola
    Agarwala, Sanjiv S.
    van Herpen, Carla M. L.
    Queirolo, Paola
    Blank, Christian U.
    Hauschild, Axel
    Beck, J. Thaddeus
    St-Pierre, Annie
    Niazi, Faiz
    Wandel, Simon
    Peters, Malte
    Zubel, Angela
    Dummer, Reinhard
    [J]. LANCET ONCOLOGY, 2013, 14 (03) : 249 - 256
  • [2] A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
    Bendell, Johanna C.
    Javle, Milind
    Bekaii-Saab, Tanios S.
    Finn, Richard S.
    Wainberg, Zev A.
    Laheru, Daniel A.
    Weekes, Colin D.
    Tan, Benjamin R.
    Khan, Gazala N.
    Zalupski, Mark M.
    Infante, Jeffrey R.
    Jones, Suzanne
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Chavira, Renae E.
    Christy-Bittel, Janna L.
    Barrett, Emma
    Patnaik, Amita
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (05) : 575 - 583
  • [3] Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
    Dummer, Reinhard
    Schadendorf, Dirk
    Ascierto, Paolo A.
    Arance, Ana
    Dutriaux, Caroline
    Di Giacomo, Anna Maria
    Rutkowski, Piotr
    Del Vecchio, Michele
    Gutzmer, Ralf
    Mandala, Mario
    Thomas, Luc
    Demidov, Lev
    Garbe, Claus
    Hogg, David
    Liszkay, Gabriella
    Queirolo, Paola
    Wasserman, Ernesto
    Ford, James
    Weill, Marine
    Sirulnik, L. Andres
    Jehl, Valentine
    Bozon, Viviana
    Long, Georgina V.
    Flaherty, Keith
    [J]. LANCET ONCOLOGY, 2017, 18 (04) : 435 - 445
  • [4] Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
    Farley, John
    Brady, William E.
    Vathipadiekal, Vinod
    Lankes, Heather A.
    Coleman, Robert
    Morgan, Mark A.
    Mannel, Robert
    Yamada, S. Diane
    Mutch, David
    Rodgers, William H.
    Birrer, Michael
    Gershenson, David M.
    [J]. LANCET ONCOLOGY, 2013, 14 (02) : 134 - 140
  • [5] Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
    Friday, Bret B.
    Adjei, Alex A.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (02) : 342 - 346
  • [6] Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
    Gershenson, David M.
    Sun, Charlotte C.
    Iyer, Revathy B.
    Malpica, Anais L.
    Kavanagh, John J.
    Bodurka, Diane C.
    Schmeler, Kathleen
    Deavers, Michael
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 661 - 666
  • [7] Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
    Gershenson, David M.
    Sun, Charlotte C.
    Bodurka, Diane
    Coleman, Robert L.
    Lu, Karen H.
    Sood, Anil K.
    Deavers, Michael
    Malpica, Anais L.
    Kavanagh, John J.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 114 (01) : 48 - 52
  • [8] MEK1/2 inhibitors in the treatment of gynecologic malignancies
    Miller, Caela R.
    Oliver, Kate E.
    Farley, John H.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (01) : 128 - 137
  • [9] Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
    Oswald, Ailsa J.
    Gourley, Charlie
    [J]. CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 412 - 419
  • [10] Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
    Schmeler, Kathleen M.
    Sun, Charlotte C.
    Bodurka, Diane C.
    Deavers, Michael T.
    Malpica, Anals
    Coleman, Robert L.
    Ramirez, Pedro T.
    Gershenson, David M.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : 510 - 514
12